New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
10:35 EDTOII, ADI, VCLK, KRO, VRX, NTRI, BPI, KKDHigh option volume stocks; DBC, VCLK, KKD, VRX, ADI, BPI, KRO, OII, NTRI
News For VCLK;KKD;VRX;ADI;BPI;KRO;OII;NTRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
17:01 EDTVRXExpress Scripts says 'scrutinizing' every Valeant prescription, Bloomberg says
According to Bloomberg, the Express Scripts Chief Medical Officer said in an interview that Valeant prescriptions are getting "extra scrutiny."
09:59 EDTOIIOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Aegerion (AEGR) downgraded to Underperform from Neutral at BofA/Merrill... Archer Daniels (ADM) downgraded to Hold from Buy at Argus... Bed Bath & Beyond (BBBY) downgraded to Perform from Outperform at Oppenheimer... Best Buy (BBY) downgraded to Perform from Outperform at Oppenheimer... Boeing (BA) downgraded to Neutral from Overweight at JPMorgan... CSX (CSX) downgraded to Market Perform from Outperform at Avondale... Comstock Resources (CRK) downgraded to Neutral from Buy at Ladenburg... EV Energy (EVEP) downgraded to Neutral from Buy at Ladenburg... FNFV (FNFV) downgraded to Market Perform from Outperform at Keefe Bruyette... Flowers Foods (FLO) downgraded to Hold from Buy at Deutsche Bank... Goldcorp (GG) downgraded to Sector Performer from Outperformer at CIBC... Group 1 Automotive (GPI) downgraded to Sector Weight from Overweight at KeyBanc... HSBC cuts Sprint (S) to sell, says competitors may make turnaround difficult... KAR Auction (KAR) downgraded to Neutral from Buy at Goldman... LINN Energy (LINE) downgraded to Sell from Neutral at Citi... LPL Financial (LPLA) downgraded to Market Perform from Outperform at Wells Fargo... Legacy Reserves (LGCY) downgraded to Neutral from Buy at Ladenburg... LinnCo (LNCO) downgraded to Sell from Neutral at Citi... Memorial Production (MEMP) downgraded to Neutral from Buy at Ladenburg... NetApp (NTAP) downgraded to Underweight from Neutral at Atlantic Equities... Netflix (NFLX) downgraded to Market Perform from Outperform at FBR Capital... Nu Skin (NUS) downgraded to Neutral from Buy at Sidoti... Oceaneering (OII) downgraded on multiple headwinds at RBC Capital... Och-Ziff Capital (OZM) downgraded to Neutral from Buy at Compass Point... Stone Energy (SGY) downgraded to Neutral from Buy at Ladenburg... Vanguard Natural (VNR) downgraded to Neutral from Buy at Ladenburg.
08:08 EDTOIIOceaneering downgraded on multiple headwinds at RBC Capital
Subscribe for More Information
February 11, 2016
12:32 EDTADIMaxim evades sell-off as the possibility of a bid from TI materializes
Shares of analog semiconductor maker Maxim Integrated Products (MXIM) are evading a broad market sell-off after research firm Macquarie mentioned the firm as a possible takeover candidate by Texas Instruments (TXN). WHAT'S NEW: In a research note from Wednesday, Macquarie analyst Deepon Nag said Texas Instruments could make a bid for Maxim Integrated. The analyst contended that although TI is in no hurry to make an acquisition, the chip giant has historically been an opportunistic buyer of distressed assets. The recent market sell off has created an opportunity in that regard as semiconductor companies are off their highs. Maxim is well off its October high of $42.18 and is currently trading at approximately $31.43 per share. The analyst believes Maxim Integrated fits Texas Instruments criteria of focusing on a strong R&D team, broad customer base, and focus on industrial and automotive end markets. Nag also believes that with additional synergies, Maxim could drive free cash flow yield of roughly 9%, above Texas' current yield of 7%. WHAT'S NOTABLE: Speaking at the Goldman Sachs Technology & Internet Conference on midday Wednesday, Texas Instruments Chief Financial Officer Kevin March spoke of the company's efforts in analog markets, especially in the automotive sector. When asked about the company's M&A strategy, March highlighted the importance of free cash flow, or FCF, that an acquisition can generate. According to Macquarie analyst Deepon Nag, a Maxim acquisition could improve TI's free cash flow yield by 2%. March stressed the importance of a strategic fit that's going to further the company's efforts in industrial and automotive. "So, when we take a look at M&A, the thing that we look at first and foremost is, does it fit our portfolio, is it strategically going to help us. Is it going to help us advance our position in industrial and automotive. It's probably going to be an analog company." said March, speaking at the Goldman conference. PRICE ACTION: Shares of Maxim are up fractionally to $31.25 in midday trading, while Texas Instruments is down over 1% to $50.13. OTHERS TO WATCH: Other chip makers in the analog space include Analog Devices (ADI) and Linear Technology Corporation (LLTC).
10:57 EDTOIIOceaneering downgraded to Underperform from Sector Perform at RBC Capital
Subscribe for More Information
February 10, 2016
17:09 EDTOIIOceaneering sees lower demand for services, products in 2016
Subscribe for More Information
17:08 EDTOIIOceaneering sees 2016 organic CapEx $150M-$200M
Approximately $75M of which is expected to be maintenance capital expenditure.
17:06 EDTOIIOceaneering says expects to maintain current dividend throughout 2016
Subscribe for More Information
17:06 EDTOIIOceaneering reports Q4 adjusted EPS 58c, consensus 58c
Subscribe for More Information
February 5, 2016
17:17 EDTVRXPershng Square raises stake in Valeant to 9% from 8.5%
Subscribe for More Information
09:43 EDTVRXValeant scripts accelerate following Walgreens Boots launch, says RBC Capital
Subscribe for More Information
February 4, 2016
12:26 EDTVRXClinton campaign posts another story targeting Valeant
In a new post to Hillary Clinton's presidential campagin website, staffer Paola Luisi notes that Clinton has previously stated, "I will have the Justice Department and every tool at my disposal to go after these companies that are doing this to people who need the help," referring to drug companies including Valeant, which is named in the post. Reference Link
11:15 EDTADIBroadcom, Analog Devices seen as beneficiaries of cellular/Wi-Fi convergence
Shares of three companies involved in cellular and Wi-Fi technology -- Broadcom Limited (AVGO), Analog Devices (ADI), and Microsemi Corporation (MSCC) -- are all trading higher after a Sterne Agee research note suggested they would benefit from a trend toward the convergences of the two communications technologies. WHAT'S NEW: On February 3, Qualcomm (QCOM) and Deutsche Telekom (DTEGY) announced that, through the aggregation of licensed and unlicensed spectrum bands, recent testing demonstrated the ability of LTE Licensed-Assisted Access, or LAA, to extend coverage and increase network capacity, while delivering seamless mobility, and ensuring a fair coexistence with Wi-Fi in unlicensed spectrum. "LAA is one of the key technologies that will help satisfy the increasing demand for data and better mobile connectivity," said Deutsche Telekom Chief Technology Officer Bruno Jacobfeuerborn. "The trial will help the wireless ecosystem and key stakeholders verify and experience the benefits of LAA first hand." WHAT'S NOTABLE: Sterne Agee CRT analyst Douglas Freedman believes the line between cellular and Wi-Fi is likely to blur, pointing to the Qualcomm-Deutsche Telekom partnership as an example of this technology trend. Freedman said three stocks that could benefit from the shift are Broadcom Limited, given its premium RF filtering and Wi-Fi connectivity solutions, Analog Devices, because of its increased data converter content in small cell applications, and Microsemi Corporation, due to its Wi-Fi access point and timing enablers. The firm has Buy ratings on all three stocks. PRICE ACTION: In late morning trading, Broadcom was trading higher by 2.2%, Analog Devices was up fractionally and Microsemi rose 1%.
09:18 EDTADISterne Agee CRT names three winners from convergence of cellular, Wi-Fi
Subscribe for More Information
09:09 EDTVRXValeant volatility up into House Oversight & Government Reform Committee hearing
Valeant January weekly call option implied volatility is at 85, February is at 71, March is at 78; compared to its 52-week range of 26 to 116, suggesting large near term price movement into House Oversight & Government Reform Committee holding a hearing to discuss methods and reasoning behind recent drug price increases with Interim CEO Hoard Schiller.
08:48 EDTVRXHouse Oversight & Government Reform Committee to hold a hearing
Subscribe for More Information
February 2, 2016
17:09 EDTOIIOceaneering announces BP terminated use of vessel Bourbon Oceanteam 101
Subscribe for More Information
12:32 EDTVRXEvercore highlights potential discrepancy in Valeant documents
Evercore ISI analyst Umer Raffat says the Valeant documents released ahead of Thursday's Congressional hearing on drug pricing contain a potential discrepancy between CEO Mike Pearson's comments on a conference call and an internal email sent by then CFO Howard Schiller. On the company's Q1 earnings call last year, Pearson told investors and analysts that volume was greater than price in terms of the company's growth in the quarter, Raffat points out to investors in an intraday research note. In contrast, then-CFO Howard Schiller sent an email to Pearson a few weeks after the earnings call stating that excluding the Marathon deal, price represented about 60% of Valeant's quarterly growth. On the surface, this means that either the CEO was inaccurate on the Q1 call, or the CFO's email was inaccurate, Raffat writes. It could also mean neither had done the math properly, the analyst adds. Either way, Raffat thinks Thursday's hearing isn't too critical for shares of Valeant. He has a Buy rating on the stock with a $200 price target. Valeant is down 5%, or $4.61, to $91.04 in midday trading.
11:30 EDTVRXValeant, in response to House committee, says tries to set appropriate prices
Valeant issued a statement after the House's Committee On Overweight and Government Reform released a letter relating to documents obtained from the company. The statement read, "Before Valeant purchased Nitropress and Isuprel, it commissioned outside consultants to review the drugs' pricing. Those consultants concluded that, given the significant reimbursements hospitals received under bundled rates for procedures, the prices of both drugs did not reflect their true value to hospitals and patients. We try to set our prices at the appropriate levels, but we also listen to the market. In this case, we've heard from hospitals, as well as from Congress, that we set the price for these two drugs too high, and we've responded by offering volume-based discounts of up to 30% for each of them. We are also making overall changes to how we run our business. Under our recent partnership with Walgreens we will be offering 10% price reductions on some of our most popular drugs and up to 95% reductions for a large number of our branded drugs for which there is a generic alternative. Going forward, we expect our growth to be driven more by volume than by price. When we set the price of any one drug, we do it in the overall context of our portfolio of approximately 1,800 products, including more than 200 prescription drugs in the United States, and the need to fund our robust companywide research and development programs, our expanding U.S. manufacturing base, and our patient assistance programs. In 2016, we expect to invest approximately $400 million on R&D, $484 million in expanding manufacturing in Rochester, NY, and $1 billion in our patient assistance programs that seek to ensure that out-of-pocket expenses do no prevent eligible patients from receiving medicines they need."
11:30 EDTVRXHouse committee members says Valeant inflated drug prices to meet goals
In a memo from the Committee on Oversight and Government Reform, Democratic members of the committee stated that documents obtained from Valeant show that the company identified goals for revenue first, then "set drug prices to reach those goals," pointing to its sharp price increases for Isuprel and Nitropress as examples of this practice. The committee also contend that Valeant employed a public relations strategy, which is noted to be used by other drug companies as well, to "distract public attention away from its price increases." Valeant raised the prices of some products multiple times from 2014 to 2015, in some cases by as much as 800%, the committee members stated. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use